In the NCT03248479 clinical trial, 64 AML patients were treated with magrolimab plus azacitidine, including 47 patients with the TP53 mutation, a treatment-refractory and poor-prognosis population with published median overall survival of 5–7 months even with HMA and venetoclax based therapies. Here, TP53 is linked to acute myeloid leukemia.